Milltrust’s investment platforms host a number of the world’s leading country and regional emerging markets asset managers from the developing world. Operating within a unique, regulated environment, these asset managers provide investors with a safe, transparent, and liquid custodial platform. The Milltrust range of funds – encompassing China, India, ASEAN, South Korea, Eurasia, Africa, and Brazil – serves as the building blocks for a truly Global Emerging Markets offering. Investors have the flexibility to engage with these markets on a stand-alone basis or through Milltrust’s discretionary-managed Global Emerging Markets Fund, unlocking a spectrum of investment opportunities in some of the most dynamic economies globally, underpinned by a unique, regulated environment ensuring transparency, liquidity, and safety.
Global Emerging Markets (GEMS)
The Milltrust Global Emerging Markets (GEMS) Fund is a multi-specialist fund that invests in a limited portfolio of regulated emerging markets equity funds. It combines Milltrust’s proprietary quantitative modelling techniques and qualitative analysis to establish the geographical allocation between the different regional investment teams that make up the emerging markets index.
Regional Funds
Access to dedicated funds targeting key emerging markets regions, allowing for focused or diversified engagement as per your investment strategy.
Local Expertise
Our investment approach favours teams with on-ground presence, ensuring direct access to extensive networks including industry leaders and government officials in the respective markets.
Research-Driven
Investment opportunities are identified through meticulous bottom-up research, leveraging company visits and management interactions, allowing for informed decision-making and potential alpha generation.
High Conviction
Aiming for a high conviction portfolio of best ideas securities across the developing world to seek strong risk-adjusted returns across market cycles.
Unique Multi-Specialist Approach
Combining local alpha generation with proprietary country allocation modelling to seek to overweight potential winners.
Customisable Mandates
Adaptable structures to accommodate diverse client requirements including risk tolerance and geographical preferences.
Professional investors are invited to delve deeper into our Emerging Markets Funds and discover how Milltrust’s unique approach aims to unlock value in the vibrant markets of the developing world.
At Milltrust, Sustainable Prosperity is a defining ethos, particularly in combating climate change. Our Climate Impact Asia Fund embodies this commitment, catalysing sustainable technology innovations in the Asia-Pacific region to balance economic growth with environmental stewardship.
Strategic Focus
Engage with innovative enterprises dedicated to climate resilience and carbon neutrality in the critical Asia-Pacific region.
Sustainable Commitment
Collaborate with companies leading in renewable energy, sustainable construction, and environmental services.
Professional Engagement
Exclusively available to professional investors who share our vision of a sustainable, low-carbon economy.
Support the momentum of renewable energy advancements in Asia, contributing to a greener tomorrow.
Invest in the sustainable transformation of urban waste management and environmental services.
Back the expansion of electric mobility and low-carbon transport solutions.
Address Asia’s water scarcity issues through sustainable consumption and innovative water management solutions.
Encourage smarter energy use in urban infrastructures, promoting green buildings
Support the development of energy efficiency technologies, contributing to reduced emissions and a path to carbon neutrality.
Multiple-award winning fund (2020, 2021, 2022, and 2023) including Best ESG Equities Fund, Best ESG Performance, Best ESG Methodology, Environmental Fund of the Year, and Impact Initiative of the Year. For a full list of awards, click here.
Professional investors are invited to explore the Climate Impact Asia Fund and discover how we are fostering responsible innovations in the heart of Asia’s climate solutions landscape.
Building upon the success of The British Innovation Fund I, the British Innovation Fund II continues to invest in high-potential companies emerging from the rich ecosystem of University Venturing. With a keen focus on agri-tech, the future of healthcare, climate impact, and alternative protein sectors, the fund is dedicated to supporting ventures where incontrovertible science forms the bedrock of the commercial proposition. This initiative embodies a One Health approach, underscoring the intrinsic connections between Food, Health, and Planet, and striving for sustainable solutions through innovative ventures.
Advancing the biofuel industry with Modified Black Soldier Fly strains for sustainable bi-products.
Revolutionising patient care by swiftly identifying chemotherapy patients at risk of neutropenic sepsis, chemotherapy patients at risk of neutropenic sepsis, optimising healthcare resources and saving lives.
Harnessing gene-editing technology to enhance livestock farming, promoting animal welfare and resource efficiency.
Learn MoreUtilising a model fusion approach to machine learning for creating diagnostic solutions to human diseases.
Learn MorePioneering animal stem cell solutions to support the global cultivated meat market and promote sustainable food production.
Learn MoreOffering a unique COVID-19 triple antibody testing device to provide real-time immunity analysis.
Learn MoreProviding biodegradable solutions for conventional plastic packaging to combat global plastic pollution.
Learn MoreRevolutionising liver biopsy procedures to enhance safety and acceptance, thereby advancing the understanding and treatment of liver disease.
Harnessing natural bioactives for innovative, eco-friendly solutions in agriculture and healthcare.
Facilitating precise cancer care pathways by connecting patients and doctors to advanced treatment options and clinical trials.
Pioneering real-time breathing analysis technology to enhance respiratory care and diagnostics.
Learn MoreLeader in plant-based culinary innovation. They have rapidly emerged as a trailblazer in plant-based food technology, leading the way in the alternative protein sector.
Professional investors are invited to delve deeper into our British Innovation Fund II and explore the innovative ventures at the heart of the One Health approach, striving to harmonise Food, Health, and Planet for a sustainable future.
Cambridge medtech start-up 52 North Health has developed an innovative device, Neutrocheck, that rapidly identifies chemotherapy patients at risk of a life-threatening complication called neutropenic sepsis. Through improving triaging, Neutrocheck has the potential to save thousands of lives, free up valuable healthcare resources, and make patients' lives easier, simpler, and better.
Jiva.ai is an AI company that uses a model fusion first approach to machine learning to provide a sophisticated platform that enables multi-modal AI, allowing non-technical users to iteratively grow, evolve and deploy models based on their data for real-world use.
Attomarker, a spin-out company from the University of Exeter, has produced a unique COVID-19 triple antibody testing device, giving a real-time analysis of immunity levels. The blood sample analysis tracks both the waning immunity from vaccines and ‘natural immunity’ boosts from COVID infections. The data it generates amounts to a personal COVID-risk profile for each individual.
Singapore-based Safe Space offers a comprehensive online and offline mental health solution using therapy sessions and other resources. Using this system, patients and therapists can connect quickly, and patients can access therapy from anywhere in the world. The Safe Space platform strengthens mental resilience by providing quality, affordable tele-therapy care and prevention education.
Oncoshot is a health insights exchange platform that leverages its proprietary clinical trial matching artificial intelligence (AI) technology to address the inefficiencies of cancer clinical trials. The platform serves as a bridge between leading regional healthcare institutions and contract research organizations (CROs) and global biotechnology and pharmaceutical companies to facilitate data-driven cancer clinical trials while accelerating enrolment into actively recruiting ones.
Eupnoos is an AI enhanced smartphone app able to use sound to objectively measure lung function in patients diagnosed with chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and interstitial lung disease (ILD).
Viome is a health testing company that uses artificial intelligence (AI) to analyze an individual’s gut biology to gain insights into their health. The service offers personalized food recommendations and made-to-order supplements according to these test results.
ExitVaccitech is a biotechnology company developing vaccines and immunotherapies for infectious diseases, specialising in T-cell immunotherapy. Having developed the Oxford/AstraZeneca vaccine and administering over 2bn doses globally, the company was listed on NASDAQ in 2021, reaching a peak valuation of $628m.
ExitTotient is an artificial intelligence-driven drug discovery platform that identifies and harnesses human-derived antibodies from individuals with exceptional immune responses. Totient was acquired by Absci for an undisclosed amount in 2021.
ExitAMLo Biosciences is translating ground-breaking research in cancer biomarkers into a revolutionary range of prognostic and companion diagnostic products to improve patient outcomes and reduce the financial burden of cancers on global healthcare economies.
ExitMyDoc is Asia’s leading telemedicine service company. MyDoc’s fully integrated online-to-offline platform streamlines all aspects of primary healthcare into one easy-to-use solution connecting patients to doctors, pharmacies, diagnostic laboratories, clinical-grade health trackers, Fortune 500 and SME employers, and insurers.
ExitBugEra improve the natural traits of the Black Soldier Fly (BSF) through genetic engineering – creating a Modified Black Soldier Fly (M-BSF). This allows BugEra to rapidly develop novel strains to deliver an array of safe and sustainable bi-products. Backed by global leader in the production of biofuel, BugEra's first strain is already delivering for the rapidly expanding biofuel industry, decarbonising transport sectors such as aviation and shipping.
Founded in 2021, Cody Genetics is an animal biotechnology company that applies gene-editing technology to benefit livestock farming. The company enables breeders to receive sperm/oocytes that not only will have a pre-determined sex, but that in turn will only produce gender-biased offspring through unassisted reproduction. The gene-editing technology offered by Cody dramatically improves animal welfare by preventing the culling of billions of animals and immensely reduces resource-use.
Roslin Technologies is a biotech company pioneering sustainable solutions to support the food and agriculture sectors. Its mission is to advance disruptive innovations to improve how we produce proteins to feed the world’s increasing population. Its primary focus is on animal stem cells – and their huge potential as ingredients for supporting the global cultivated meat market..
Polymateria provides a tailored biodegradable solution for conventional plastic packaging, aiming to stem the global plastic pollution endemic. In 2020, the privately owned company was the first to achieve certified biodegradation of the most commonly-littered forms of plastic packaging in real-world conditions, in less than a year without creating microplastics.
Green Bioactives, a University of Edinburgh start-up, have developed innovative strategies to produce plant-derived natural products utilising plant cell culture with full freedom to operate. These technologies can significantly improve the yields of target natural products in cultured plant cells. This technology platform can be employed to produce high quality natural product ingredients for the cosmetic, pharmaceutical, food and agricultural industries.
Cambridge-based PragmatIC is a world leader in ultra-low-cost flexible electronics. Their flexible integrated circuits (FlexICs) are thinner than a human hair and can be invisibly embedded in objects, enabling innovators to create novel solutions to everyday problems that are not practical with conventional electronics.
CorePower is a UK-based development company, specializing in scalable atomic power technology for ocean transport and heavy industry. In partnership with leading international corporations, CorePower aims to deliver durable zero-emission energy for floating industrial production and deep-sea shipping.
British Care Investments (BCI) is a specialised healthcare real estate investment vehicle crafted with the objective of delivering stable returns supported by robust contractual agreements. Through investments in a diversified portfolio of care home assets in the United Kingdom, and leasing them to ‘Tier 1’ operators, BCI aims to foster a conducive environment for quality care delivery while ensuring a balanced investment outlook.
The initiative stems from a unique collaboration between the experienced real asset manager, Milltrust International, and the world-renowned care home operator, AcalisCare. This alliance strives to offer shareholders an attractive blend of contractually assured yield and capital appreciation by navigating the evolving landscape of the UK’s care home sector.
Significant tailwinds are being driven by demographic changes, consolidation of smaller homes, a new regulatory framework (CQC), demand and supply imbalances, and increasing demand for high-quality care home accommodation.
BCI provides a unique opportunity for shareholders to capitalise upon the current special market conditions:
The growth in demand comes from the fact that the population of elderly people (aged 75-84) is forecast to almost double over the next 50 years, from 6 million to 12 million. The over-85 population group are expected to double within only 20 years to 3.4 million. In addition, most of these individuals will spend the last 15 years of their life with some ill health.
Although the demand for care homes and specialist care is clear, there is a failure of supply to match this rising demand. There has been a 17% decrease in the total number of beds from 2012 to 2021; from 11.3 to 9.4 (beds per 100 over 75s). More than 100,000 new beds will be required in the next 10 years, with an estimated for 350,000 in 2050. The COVID-19 pandemic has exacerbated this shortfall, lowering the number of registered care home beds by 2.4%.
The quality of care in existing care homes is highly fragmented, as most of the market is constituted of small or single owner care homes. According to the CQC 21% of homes are either ‘inadequate’ or ‘need improvement’. This presents opportunities for consolidation and improvement in both professionalism and in efficiencies.
Milltrust brings a 13-year track record in managing investments, including Public Funds and Private Funds.
AcalisCare brings 18 years of Care Home management across the Globe and has the required expertise to improve and manage care homes effectively. The team is highly experienced in sourcing, managing and exiting properties in the Care Home sector.
Together, we combine world-class expertise in investment and care home management to bring you British Care Investments.
Professional investors are invited to delve deeper into British Care Investments, exploring a unique proposition at the intersection of real estate investment and quality healthcare provision.
6 Stratton Street
London W1J 8LD
United Kingdom
Tel: +44 (0)20 8123 8316
Email: [email protected]
77B Tras Street
Singapore 078978
Tel: +65 6225 3052
Fax: +65 6225 3072
Email: [email protected]